Ohio DEA DATA 2000 One-and-a-Half-Day Waiver Training: Wooster, Ohio: April 06-07, 2018

Product not yet rated

  • Registration Closed

   image       image     image

Ohio DEA DATA 2000 

One and a Half Day Waiver Training

 Day 1: 8-Hour ASAM DATA 2000 Course

Friday, April 06, 2018 
8:30 am - 5:30 pm

Gault Liberty Center
104 Spink Street
Wooster, Ohio, 44691

DAY 2: 4-Hour OhioMHAS Implementation Training

Saturday, April 07, 2018 
8:30 am - 12:30 pm

Gault Liberty Center
104 Spink Street
Wooster, Ohio, 44691

This course is offered in partnership with the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and Substance Abuse and Mental Health Service Administration (SAMHSA). The curriculum for this course has been specifically designed for Ohio licensed physicians, nurse practitioners, and physician assistants.

Welcome to the Ohio DEA DATA 2000 One and a Half Day Waiver Training. Please LOG IN or Create a New Account to register for the course. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

The 8-hour section of the training provided by the American Society of Addiction Medicine (ASAM) covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This course is SAMHSA-supported. 

The 4-hour section of the training provided by OhioMHAS is required to receive your reimbursement and will include training from experts around Ohio that will enhance the prescriber’s knowledge about opioid prescribing and buprenorphine policies (e.g., low-dose prescribing according to federal and state guidelines and DEA guidance on documentation). 

 Once you have completed the entire day and a half training, return to the ASAM e-Learning Center and complete the necessary steps listed in the "content" tab to obtain your reimbursement.  If you have any questions, please contact education@ASAM.org


Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD  
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.

This training is divided into two parts of 8 hours and 16 hours. This 8 hour course will satisfy Part 1 and Part 2 can be completed online for free.

For NPs (CE Credit through AANP): Click Here   

For PAs (AAPA Category 1 CME Credit): Click Here

Funding for this conference was made possible (in part) by the Ohio Opioid STR Project- 1H79TI080261-01 grant from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Key:

Complete
Failed
Available
Locked
Treatment of Opioid Use Disorder: Waiver Qualifying - Wooster, Ohio - Friday, April 06, 2018
04/06/2018 at 8:30 AM (EDT)   |  0 minutes
04/06/2018 at 8:30 AM (EDT)   |  0 minutes
Live Implementation Half-Day Training - Wooster, Ohio, Saturday, April 07, 2018
04/07/2018 at 8:30 AM (EDT)   |  0 minutes
04/07/2018 at 8:30 AM (EDT)   |  0 minutes
Complete Post-Course CME Evaluation
21 Questions
Download CME Certificate
Up to 8.00 medical credits available  |  Certificate available
Up to 8.00 medical credits available  |  Certificate available 8 Credits
Send your CME Certificate to SAMHSA
Apply For Your Waiver
Select the "Apply For Your Waiver" button to begin.
Select the "Apply For Your Waiver" button to begin. Providers, please follow this link to apply for your waiver:
Download W-9 Form
Open to download resource.
Open to download resource. Please complete W-9 Form and upload it in the next component.
Upload W-9 Form
Graded as Pass/Fail
Graded as Pass/Fail After downloading and filling out the W-9 form, please upload the completed document here. We will use this information to distribute your reimbursement.
Enter DEA X Number
1 Question
Upload Copy of DEA X Number
Graded as Pass/Fail | Due Date: 06/28/2018
Graded as Pass/Fail | Due Date: 06/28/2018 In order to receive your reimbursement, you must scan a copy of your DEA X Number and upload that file here. One this is uploaded, we will give you your reimbursement.
Need Help?
Contact Us
Contact Us If you need help or have questions about this process ​please email education@asam.org ​or call 301.656.3920 and ask to speak with an education team member​.

Click here for additional resources.

CME Information and Disclosure Listing

Date of Release: July 2015 Approved Through: July 2018

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits

This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM CME Committee

Name

Nature of Relevant Financial Relationship

Commercial Interest

What was received?

For what role?

Catherine Friedman, MD, FAPA, FASAM

Chair

None

Edwin A. Salsitz, MD, FASAM

None

Herbert Malinoff, MD, FACP, FASAM

None

Noel Ilogu, MD, MRCP

None

John Tanner, DO, FASAM

Reckitt Benckiser

OREXO

BDSI
Honorarium

Honorarium

Honorarium
Speaker

Speaker

Speaker and Consultant

ASAM Buprenorphine Program Planning Committee

Name

Nature of Relevant Financial Relationship

Commercial Interest

What was received?

For what role?

Dan Alford, MD, MPH

None

Andrew J. Saxon, MD

UpToDate

Royalties

Section Editor, Drug Use Disorders

Colleen LaBelle, BSN, RN-BC, CARN

None 

Edwin Salsitz, MD, FASAM

None

Jeffrey D. Baxter, MD

None 

Kelley Saia, MD

None

Sharon Levy, MD, MPH

None

Paula J. Lum, MD, MPH

None

ASAM Buprenorphine Course Faculty

Name

Nature of Relevant Financial Relationship

Commercial Interest

What was received?

For what role?

Edwin Salsitz, MD, FASAM

None

Andrew J. Saxon, MD

UpToDate

Royalties

Senior Editor, Drug Use Disorders

Colleen LaBelle, BSN, RN-BC, CARN

None

Dan A. Alford, MD, MPH

None

Jeffrey D. Baxter, MD

None

Kelley Saia, MD

None

Sharon Levy, MD, MPH

None

Paula J. Lum, MD, MPH

None

Sarah Bagley, MD

ASAM Millennium Fellowship Award

Partial Salary Support

Awardee

Alexander Y. Walley, MD, MSc

None

ASAM CME Committee Reviewers

Name

Nature of Relevant Financial Relationship

Commercial Interest

What was received?

For what role?

Adam J. Gordon, MD, MPH, FACP, FASAM 

None

Herbert Malinoff, MD, FACP, FASAM 

None

Funding for this conference was made possible (in part) by the MHA-18-MEDDIR-DATA 2000 WAIVER-19 grant from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

At the conclusion of this activity, learners should be able to:

  1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
  2. Identify and assess patients who are appropriate for treatment with medications
  3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
  4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

Licensed physicians, nurse practitioners, and physician assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.

Claiming CME Credit

  1. Under the “Contents” tab locate the step “Complete Post-Course CME Evaluation”
  2. Fill out the survey by clicking the blue “Fill out Survey” button
    1. Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window
  3. Submit the evaluation (the next box should activate, and the CME evaluation box should turn green with a white check mark)
  4. Click the button “Claim Medical Credits” in the box titled “Download CME Certificate”
  5. Choose the type of credit (Physician or Non-physician) and click submit
  6. Click the button “View/Print Certificate” to save or print your certificate
    1. Pro tip: If you ever lose your certificate, you can come back to the ASAM e-Learning Center and view it on your Transcript (found on Dashboard)


Apply

NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

Qualify

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD  
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.